Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 244

Sort by

Sort Order Select

Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Blood (2025) 146 (Supplement 1): 681.

https://doi.org/10.1182/blood-2025-681

Published: 2025

Journal Articles

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Blood (2025) 146 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2025-2037

Published: 2025

Journal Articles

Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer

Blood (2025) 146 (Supplement 1): 2024.

https://doi.org/10.1182/blood-2025-2024

Published: 2025

Journal Articles

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

Blood (2025) 146 (Supplement 1): 2053.

https://doi.org/10.1182/blood-2025-2053

Published: 2025

Journal Articles

RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia

Naseema Gangat, Ayalew Tefferi, Prithviraj Bose, Elizabeth Hexner, Laura Michaelis, Aaron Gerds, Akriti Jain, Prioty Islam, Raajit Rampal, Ronan Swords, Moshe Talpaz, Kristen Pettit, Sima Bhatt, Akshay Buch, Olivia Pelletier, Will Savage, Anna Halpern

Blood (2025) 146 (Supplement 1): 2042.

https://doi.org/10.1182/blood-2025-2042

Published: 2025

Journal Articles

Preclinical efficacy of dual BET/HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells

Warren Fiskus, Christopher Mill, Lucia Masarova, Naveen Pemmaraju, Prithviraj Bose, Arnav Gupta, Hanxi Hou, Taghi Manshouri, Jayastu Senapati, Sanam Loghavi, Andrew Dunbar, Claes Wahlestedt, Courtney DiNardo, Kapil Bhalla

Blood (2025) 146 (Supplement 1): 5053.

https://doi.org/10.1182/blood-2025-5053

Published: 2025

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)

Linda Fabris, Warren Fiskus, Kavi O'Connor, Zachary Zaroogian, Shishir Waghray, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Lucia Masarova, Taghi Manshouri, Kapil Bhalla, Claes Wahlestedt, Ross Levine, Andrew Dunbar

Blood (2025) 146 (Supplement 1): 3759.

https://doi.org/10.1182/blood-2025-3759

Published: 2025

Journal Articles

Integrative proteomics and machine learning identify subtype- and symptom-associated signatures in systemic mastocytosis

Wei Xiao, Annie Hoai Nguyen, Ivo Veletic, Taghi Manshouri, Naveen Pemmaraju, Lucia Masarova, Prithviraj Bose, Hussein Abbas

Blood (2025) 146 (Supplement 1): 3758.

https://doi.org/10.1182/blood-2025-3758

Published: 2025

Journal Articles

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

Blood (2025) 146 (Supplement 1): 89.

https://doi.org/10.1182/blood-2025-89

Published: 2025

Journal Articles

Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial

Jeanne Palmer, Jonathan How, Prithviraj Bose, Pankit Vachhani, Adam Mead, Jonathan Sillar, Aaron Gerds, Angela Fleischman, Caitlin O'Neill, Ross Baker, Ronald Hoffman, Shiangtung Jung, Jon Ruckle, Keyvan Yousefi, Sanjay Bhanot, Terry Barrett, Ruben Mesa

Blood (2025) 146 (Supplement 1): 82.

https://doi.org/10.1182/blood-2025-82

Published: 2025

Journal Articles

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Lindsay Rein, Nathan Boggs, Prithviraj Bose, Brian Modena, Vito Sabato, Karin Hartmann, Cem Akin, Tracy George, Cecilia Arana Yi, Hanneke Oude Elberink, Deepti Radia, Andreas Reiter, Miguel Piris-Villaespesa, Ingunn Dybedal, Jens Panse, Stephen Oh, Pankit Vachhani, Anthony Hunter, Mariana Castells, Cristina Bulai Livideanu, Paul van Daele, Arnold Kirshenbaum, Ivan Alvarez-Twose, Jennifer Vaughn, Minakshi Taparia, Sonia Cerquozzi, Andrzej Mital, Marek Hus, ALESSANDRA ROMANO, John Fahrenholz, Frederick Lansigan, Cristina Papayannidis, Helena Pomares, Michela Rondoni, Celalettin Ustun, Richard Herrscher, Michael Manning, Stéphane Barete, Mar Guilarte, Candido Rivera, Jonathan Bernstein, Peter Vadas, Chiara Elena, Derek McCulloch, Nina Orfali, Clodagh Keohane, Francesco Mannelli, Philippe Schafhausen, Amanda Pilla, Jenna Zhang, Lei Sun, Nisha Shah, Hina Jolin, Rachael Easton, Jessica Sachs, Frank Siebenhaar, Daniel Deangelo

Blood (2025) 146 (Supplement 1): 80.

https://doi.org/10.1182/blood-2025-80

Published: 2025

Journal Articles

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Blood (2025) 146 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2025-4613

Published: 2025

Journal Articles

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Blood (2025) 146 (Supplement 1): 7353.

https://doi.org/10.1182/blood-2025-7353

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor (JAKi) treated with imetelstat (IME) in the imbark trial

John Mascarenhas, Claire Harrison, Alessandro Lucchesi, Angela Fleischman, Rami Komrokji, Alessandro Maria Vannucchi, Jean-Jacques Kiladjian, Yiqun Yang, Libo Sun, Ying Wan, Michelle Mudge-Riley, Tymara Berry, Faye Feller, Fei Huang, Prithviraj Bose

Blood (2025) 146 (Supplement 1): 5585.

https://doi.org/10.1182/blood-2025-5585

Published: 2025

Journal Articles

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

Raajit Rampal, Prithviraj Bose, Vikas Gupta, Francesca Palandri, Shiyuan Zhang, Jessica Lim, Fulya Sen Nikitas, Tom (sizhu) Liu, Jasmine Sahni, Catherine Ellis, Dwaipayan Patnaik, Florian Heidel, Francesco Passamonti

Blood (2025) 146 (Supplement 1): 5579.

https://doi.org/10.1182/blood-2025-5579

Published: 2025

Journal Articles

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Blood (2025) 146 (Supplement 1): 5574.

https://doi.org/10.1182/blood-2025-5574

Published: 2025

Journal Articles

Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database

Prithviraj Bose, Taylor Schwartz, Jennifer Repp, Alexis Garduno, Shayna Adams, Ahmad Naim, Valkal Bhatt, Jingbo Yu

Blood (2025) 146 (Supplement 1): 6391.

https://doi.org/10.1182/blood-2025-6391

Published: 2025

Journal Articles

Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen

Ivo Veletic, Taghi Manshouri, Christopher Pacheco, Christopher Ly, C. Cameron Yin, Jared Burks, Naveen Pemmaraju, Lucia Masarova, Prithviraj Bose, Hussein Abbas, Andrew Dunbar

Blood (2025) 146 (Supplement 1): 5542.

https://doi.org/10.1182/blood-2025-5542

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia

Preclinical efficacy of dual BET/HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)

Integrative proteomics and machine learning identify subtype- and symptom-associated signatures in systemic mastocytosis

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor (JAKi) treated with imetelstat (IME) in the imbark trial

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database

Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only